- Conditions
- Amorphous, Eosinophilic, and Acellular Deposit, Constipation, Diarrhea, Early Satiety, Gastrointestinal Hemorrhage, Hepatomegaly, Lymphadenopathy, Macroglossia, Nausea, Primary Systemic Amyloidosis, Purpura, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis
- Interventions
- Isatuximab, Laboratory Biomarker Analysis
- Biological · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 345
- States / cities
- Anchorage, Alaska • Hot Springs, Arkansas • Burbank, California + 234 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 33
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Plasma Cell Myeloma
- Interventions
- isatuximab SAR650984, lenalidomide, dexamethasone
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 5
- States / cities
- San Francisco, California • Tampa, Florida • St Louis, Missouri + 2 more
- Conditions
- Multiple Myeloma
- Interventions
- Isatuximab (for run-in portion), Isatuximab (for expansion), Pomalidomide, Elotuzumab, Dexamethasone
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Milwaukee, Wisconsin
- Conditions
- Plasma Cell Myeloma
- Interventions
- Isatuximab SAR650984, Bortezomib, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 475 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 5
- States / cities
- Fort Myers, Florida • St. Petersburg, Florida • Kansas City, Missouri + 2 more
- Conditions
- T-cell Type Acute Leukemia-Precursor, T-lymphoblastic Lymphoma/Leukaemia
- Interventions
- Isatuximab SAR650984, dexamethasone, acetaminophen, ranitidine, diphenhydramine
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Hackensack, New Jersey • Houston, Texas
- Conditions
- Hematological Malignancy
- Interventions
- Isatuximab SAR650984, Dexamethasone
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 351 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2023
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • San Francisco, California • Atlanta, Georgia + 13 more
- Conditions
- Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Carfilzomib, Isatuximab, Pomalidomide
- Drug · Biological
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Plasma Cell Myeloma
- Interventions
- Isatuximab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • San Francisco, California • Detroit, Michigan + 7 more
- Conditions
- AL Amyloidosis
- Interventions
- Bortezomib, Cyclophosphamide, Dexamethasone, Isatuximab
- Drug · Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 6
- States / cities
- Orange, California • Atlanta, Georgia • Detroit, Michigan + 2 more
- Conditions
- Neoplasm
- Interventions
- Isatuximab SAR650984, Atezolizumab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 3
- States / cities
- Santa Monica, California • Boston, Massachusetts • Houston, Texas
- Conditions
- Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Dexamethasone, Echocardiography, Isatuximab, Questionnaire Administration, Universal Donor Expanded TGF-beta-imprinted NK Cells
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Elvira Umyarova
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Plasma Cell Myeloma Recurrent
- Interventions
- Isatuximab IV, Isatuximab SC, Dexamethasone, Pomalidomide, Montelukast, Paracetamol / Acetaminophen, Diphenhydramine, Methylprednisolone
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 531 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 13
- States / cities
- Aurora, Colorado • Jacksonville, Florida • Plantation, Florida + 10 more
- Conditions
- Prostate Cancer, Non-small Cell Lung Cancer
- Interventions
- Isatuximab SAR650984, Cemiplimab REGN2810
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Hackensack, New Jersey + 2 more
- Conditions
- Plasma Cell Myeloma
- Interventions
- isatuximab SAR650984, Pomalidomide, Dexamethasone, Carfilzomib
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 583 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 24
- States / cities
- Little Rock, Arkansas • Fullerton, California • San Francisco, California + 21 more
- Conditions
- Smoldering Plasma Cell Myeloma
- Interventions
- Isatuximab, Laboratory Biomarker Analysis
- Biological · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2030
- U.S. locations
- 3
- States / cities
- New York, New York • Houston, Texas
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Interventions
- Isatuximab, Dexamethasone or equivalent, Fludarabine, Cytarabine, Liposomal daunorubicin, Daunorubicin (nonliposomal), Idarubicin, Filgrastim or equivalent, Mitoxantrone, Doxorubicin, Vincristine, Pegaspargase (PEG) Asparaginase, Cyclophosphamide, Etoposide, Methotrexate, L - Asparginase, Hydroxyurea, L - Asparaginase (Erwinase)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 28 Days to 17 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee • Dallas, Texas
- Conditions
- Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Carfilzomib, Dexamethasone, Isatuximab, Pomalidomide, Bone Marrow Biopsy, Bone Marrow Aspiration, Skeletal Survey X-Ray, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging
- Drug · Biological · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Plasma Cell Myeloma Refractory
- Interventions
- Isatuximab, Dexamethasone, Pomalidomide, Belantamab mafodotin, Pegenzileukin, SAR439459, Belumosudil, Evorpacept
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Ann Arbor, Michigan + 2 more
- Conditions
- Plasma Cell Myeloma
- Interventions
- Isatuximab, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 2
- States / cities
- Plantation, Florida • Boston, Massachusetts
- Conditions
- Plasma Cell Myeloma
- Interventions
- Isatuximab intravenous (IV), Cemiplimab (SAR439684), Dexamethasone, Lenalidomide, Pomalidomide, Isatuximab subcutaneous (SC), Carfilzomib
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Immune System Disorder
- Interventions
- Isatuximab SAR650984, Acetaminophen (paracetamol) or equivalent, Ranitidine or equivalent, Diphenhydramine or equivalent, Methylprednisolone or equivalent, Montelukast or equivalent
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 4
- States / cities
- San Francisco, California • Rochester, Minnesota • New York, New York + 1 more
- Conditions
- Plasma Cell Myeloma
- Interventions
- Isatuximab SAR650984, Lenalidomide, Dexamethasone, Montelukast or equivalent, Acetaminophen, Diphenhydramine or equivalent, Methylprednisolone or equivalent
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 337 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2033
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Denver, Colorado • Jacksonville, Florida + 6 more
- Conditions
- Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma
- Interventions
- Isatuximab, Belantamab mafodotin, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Plasma Cell Myeloma Refractory
- Interventions
- Isatuximab SC-OBDS, Montelukast, Dexamethasone, Acetaminophen, Diphenhydramine, Methylprednisolone, Carfilzomib
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Los Angeles, California • West Hollywood, California + 29 more